Clinical Efficacy of Efalizumab in Patients With Chronic Plaque Psoriasis: Results From Three Randomized Placebo-Controlled Phase III Trials: Part I

By Pariser David   Gordon Kenneth   Papp Kim   Leonardi Craig   Kwon Paul   Compton Peter   Rundle Amy   Walicke Patricia   Lebwohl Mark  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 6, 2005-12 ,pp. : 303-312

Springer Publishing Company

Access to resources Recommend Favorite

Efalizumab: Integrating a new biologic agent into the long-term management of moderate to severe plaque psoriasis

By Lynde Charles  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 1-3

Springer Publishing Company

Access to resources Recommend Favorite

Strategies for optimizing treatment with efalizumab in moderate to severe psoriasis

By Papp Kim   Ho Vincent   Langley Richard   Lynde Charles   Poulin Yves   Shear Neil   Toole John   Zip Catherine  

Journal of Cutaneous Medicine and Surgery, Vol. 9, Iss. 1, 2005-12 ,pp. : 26-32

Springer Publishing Company

Access to resources Recommend Favorite

Impact of adalimumab treatment on patient-reported outcomes: Results from a Phase III clinical trial in patients with moderate to severe plaque psoriasis

By Revicki Dennis   Willian Mary Kaye   Menter Alan   Gordon Kenneth   Kimball Alexa   Leonardi Craig   Langley Richard   Kimel Miriam   Okun Martin  

Journal of Dermatological Treatment, Vol. 18, Iss. 6, 2007-01 ,pp. : 341-350

Informa Healthcare

Access to resources Recommend Favorite

Methotrexate versus hydroxycarbamide (hydroxyurea) as a weekly dose to treat moderate-to-severe chronic plaque psoriasis: A comparative study

By Ranjan Nitin   Sharma Nand Lal   Shanker Vinay   Mahajan Vikram   Tegta Gita Ram  

Journal of Dermatological Treatment, Vol. 18, Iss. 5, 2007-01 ,pp. : 295-300

Informa Healthcare

Access to resources Recommend Favorite